OVCA1 expression and its correlation with the expression levels of cyclin D1 and p16 in cervical cancer and intraepithelial neoplasia

Abstract

Abstract. The present study aimed to examine the associations between the protein and mRNA expression levels of ovarian cancer gene 1 (OVCA1), cyclin D1 and p16 and high-risk human papillomavirus (HR-HPV) infection in cervical lesions. The protein expression levels of OVCA1, cyclin D1 and p16 in 66 cases of cervical cancer, 64 cases of cervical intraepithelial neoplasia (CIN) and 34 normal cervix tissues were detected using immunohistochemistry. The mRNA expression levels of OVCA1, cyclin D1 and p16 in cervical cancer and normal cervix cells were detected using real-time polymerase chain reaction. The results revealed that the protein expression levels of OVCA1 increased gradually, whereas its mRNA expression levels decreased gradually, in the progression from normal cervix tissue to CIN and cervical cancer (P<0.01). In addition, significant differences in the protein expression levels of OVCA1 between low-and high-level CIN, as well as between the early and advanced stages of cervical cancer, were observed (P<0.05). No significant associations were detected between the protein and mRNA expression levels of OVCA1 and the pathological type of cervical cancer or the presence of lymph node metastasis (P>0.05). The expression levels of OVCA1 mRNA and protein were positively correlated with the levels of p16 expression (P<0.01). Significant differences were also observed in the OVCA1 protein and mRNA expression levels between the HR-HPV (+) and HR-HPV (-) groups (P<0.05). Therefore, aberrant expression of OVCA1 protein and mRNA may be important during the development of cervical lesions, particularly in the early stages. In addition, the mechanisms underlying the effects of OVCA1 during cervical cancer development may involve p16 and HPV, as the levels of OVCA1 in cervical lesions were correlated with abnormal expression of p16 and HR-HPV infection. IntroductionCervical cancer is the second most common cancer in females worldwide, ranking first in developing countries (1). In recent years, the incidence of cervical adenocarcinoma and cervical cancer in young women has increased significantly; therefore, early diagnosis is of high importance (2-8). High-risk human papillomavirus (HR-HPV) infection is an established cause of cervical cancer and this disease is preventable and treatable. Although extensive screening of cervical cancer enables early diagnosis and treatment in an increasing number of patients, the detection of cervical cancer using the HR-HPV ThinPrep cytology test may lead to overtreatment and misdiagnosis, which may also impede prevention and therapeutic intervention. Furthermore, the clinical outcomes of the same treatment for similar pathological types of cervical cancer are heterogeneous (9). Therefore, an effective molecular marker of cervical lesions is required to supplement screening for cervical cancer, in order to allow the development of individual treatment regimens for various molecular types and improve the prevention and treatment of cervical cancer.Ovarian cancer gene 1 (OVCA1) is a cance...

Cyclin D1 protein affecting global women’s health by regulating HPV mediated adenocarcinoma of the uterine cervix

“… 15 and Tong et al . 18 recruited 15 and 6 ADC cases respectively and concluded Cyclin D1 as highly expressed invasion marker. Our results are in concordance with Balan et al .…”

Genome-Wide CRISPR Screening Identifies the Tumor Suppressor Candidate OVCA2 As a Determinant of Tolerance to Acetaldehyde

“…Unlike OVCA1, ectopic expression of OVCA2 in ovarian cancer cells does not suppress cell proliferation (Bruening et al, 1999). Accordingly, the tumor suppressor role of OVCA1 (DPH1), but not OVCA2, was highlighted in multiple studies (Chen and Behringer, 2004;Kong et al, 2011;Tong et al, 2017). OVCA1 and OVCA2 genes partially overlap but do not share coding regions and OVCA1 was not identified in our screen.…”

Cervical Carcinoma: Oncobiology and Biomarkers

“…HPV DNA, E6/E7 mRNA p53, Rb, p16INK4a, telomerase RNA gene (TERC), serum SCC-Ag, OCVA1 [8,[10][11][12][13]15,[20][21][22][23][24][25][26] Markers of cell cycle and proliferation Ki-67, cyclin D1, p53, p63 [12,[26][27][28][29][30][31][32][33][34][35][36] Markers of apoptosis P53, BCL-2, BCL-XL, BAX [10,27,[37][38][39][40][41][42][43][44] Expression of cytokeratins-markers of differentiation CK7, CK8, CK17, CK19 [27,36,37,[45][46][47][48][49] Markers of cell adhesion, invasion and metastasis E-cadherin, P-cadherin, CD44, ADAM9, MT1-MMP, TIMP-1, TIMP-2, MT1-MMP, MMP-2, MMP-1, MMP-9, MMP-14, proMMP-14 furin, gelatinase, TIMP-1 and TIMP-2 [27,[50][51][52]…”

“…Expression of cyclin D1 in CIN and cervical cancer was evaluated in comprehensive research on the relationship between the levels of immunohistochemical expression of protein and mRNA of ovarian cancer gene 1 (OVCA1), cyclin D1, and p16 and infection with high-risk human papillomavirus [26]. It was found that the expression of proteins OVCA1, cyclin D1, and p16 increased in CIN and cervical cancer.…”